These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9218853)

  • 1. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C.
    Anderson FH; Zeng L; Yoshida EM; Rock NR
    Can J Gastroenterol; 1997; 11(4):294-7. PubMed ID: 9218853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients.
    Fabris P; Tositti G; Negro F; Marranconi F; Infantolino D; Rassu M; De Lalla F
    Aliment Pharmacol Ther; 1999 Oct; 13(10):1329-34. PubMed ID: 10540048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study.
    Andreone P; Cursaro C; Gramenzi A; Fiorino S; Di Giammarino L; Miniero R; D'Errico A; Grigioni WF; Gasbarrini G; Bernardi M
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):688-94. PubMed ID: 10730561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial.
    Muñoz AE; Levi D; Podestá A; Gorín JM; González J; Bartellini MA; Munne MS; Cabanne A; Flichman D; Terg R
    Gut; 2000 Mar; 46(3):427-31. PubMed ID: 10673309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
    Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
    Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.
    Hwang SJ; Chan CY; Lu RH; Wu JC; Lee SD
    J Interferon Cytokine Res; 1995 Jul; 15(7):611-6. PubMed ID: 7553231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
    Iino S; Hino K; Kuroki T; Suzuki H; Yamamoto S
    Dig Dis Sci; 1993 Apr; 38(4):612-8. PubMed ID: 8384980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C.
    Massirer KB; Hirata MH; Silva AE; Ferraz ML; Nguyen NY; Hirata RD
    Braz J Med Biol Res; 2004 May; 37(5):643-7. PubMed ID: 15107924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial.
    Canbakan B; Senturk H; Tabak F; Akdogan M; Tahan V; Mert A; Sut N; Ozaras R; Midilli K; Ozbay G
    J Gastroenterol Hepatol; 2006 Apr; 21(4):657-63. PubMed ID: 16677149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of interferon combined glycyrrhizin therapy in patients with chronic hepatitis C resistant to interferon therapy].
    Okuno T; Arai K; Shindo M
    Nihon Rinsho; 1994 Jul; 52(7):1823-7. PubMed ID: 8078202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oxidative stress in patients with chronic hepatitis B before and after interferon alpha-2b treatment].
    Fan YC; Wang K; Han LY; Li XH; Wang HM; Wang LY; Hou YD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):23-5. PubMed ID: 17429526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
    De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
    J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy.
    Boran M; Cetin S
    Nephron; 1999; 82(1):22-6. PubMed ID: 10224480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to alpha 2B interferon (IFN) treatment in a haemodialysis patient with chronic hepatitis C.
    Barril G; Schez Tomero JA; Garcia Buey L; Motellon JL; Bernis C; Traver JA
    Nephrol Dial Transplant; 1994; 9(9):1354-5. PubMed ID: 7816309
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
    Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
    Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
    Bizollon T; Ahmed SN; Radenne S; Chevallier M; Chevallier P; Parvaz P; Guichard S; Ducerf C; Baulieux J; Zoulim F; Trepo C
    Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.